Bioton buys Biopartners Holding


Warsaw – Bioton, the Polish manufacturer of recombinant human insulin and antibiotics, has acquired the Swiss bio­similars company Biopartners Holding AG for approximately a59 million, including its subsidiaries in Germany and Switzerland. With this acquisition, Bio­ton has broadened its drug pipeline with five biosimilar products (see table) in advanced development, with a huge market potential. The market size of the already EU-approved but not yet marketed bio­similar Valtropin (somatropin), a recombinant human growth hormone, is estimated to achieve US$ 550 million in 2007. Bioton stated that the purchase of Biopartners will add biotechnological know-how in product development to Bioton’s own capabilities and that it will speed up the registration process for products developed by Bioton.
Bioton will purchase the Swiss company from DLJ Merchant Banking Partners, which will trade in 100% of the shares in BioPartners for 81,489,729 I-series Bioton shares, representing about 3% of its capital. The price includes the repayment of Biopartners’ debts of $15.8m (a12m) to DLJ. DLJ has undertaken not to trade its Bio­ton shares for six months from the transaction date.
Biopartners stated that its operations will not be affected by the acquisition and that it will continue its activities under the same management team.
Bioton’s CEO, Adam Wilczega, stated that BioPartners product portfolio offers an additional significant market opportunity, due to low production costs and price competitiveness.
Biopartners’ Valtropin received EU approval in April 2006 and the company announced that it would begin marketing in the UK in the second quarter of 2007. In contrast, Alpheon, a biosimilar recombinant interferon alpha, which can be used in combination with ribavirin to treat Hepatitis C and for the treatment of different cancers, failed to receive EU market approval in June 2006. Another pipeline drug (Ravanex), which combines recombinant interferon alpha with ribavirin, is expected to be launched at the beginning of the next year. Whilst Bioton plans to invest a13 million into biosimilar research in 2007 and in 2008, the company expects to increase its revenues of C45 million for this year to C78 million, when all biosimilars will be traded. “The acquisition of Biopartners is the next step towards building a modern company which will be present in all global markets”, said CEO Wilczega.



Polish antibody development and manufacturing specialist Mabion S.A. more than tripled its revenues in 2011 (€2.5m) compared to 2010 (€0.74m). The increase in turnover mainly resulted from stronger client demand for R&D services...



Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman...



Zug/Warsaw - The fourth largest generics producer and a polish biotech want to create a stir in the market for diabetes drugs. Swiss Actavis and Bioton from Warsaw announced that they have formed a joint venture company for the...



Krakow – Polish Selvita S.A., which offers preclinical drug development services to pharma companies, has been ranked as the No. 1 “Rising Star” of this year’s Fast50 contest. In the programme, analysts from Deloitte Technology...



Warsaw – Poland’s Bioton S.A. has announced it is investing €20m in a new production plant in Szczecin. The biotechnology company is planning to manufacture insulin injection devices in the facility. The project involves the...



Warsaw – Biotech experts want to make the development of pharmaceutical and medical innovations a priority in Poland. At the start of September, members of the Polish Technology Platform for Innovative Medicine recommended that...



Kraków – Selvita SA CEO Pawel Przewiezlikowski announced at the end of July that the Polish drug development and drug discovery service firm is close to achieving profitability. After bagging EUR3.7m through an IPO on Warsaw’s...



Warsaw – Researchers from Lodz and Poznan Universities say Poland needs to update its draft GMO law. “The national current legal situation is complicated,” Prof. Tomas Twardowski told EuroBiotechNews, stressing that while trade...



Krakow – Polish Selvita S.A. is going public. By May, the drug discovery specialist announced it had entered into definite agreements with investors to sell 2.7 million shares for a total of EUR3.75m, resulting in a market...



Szczecin/Greifswald – A team of physical chemists headed by Robert Hoylst from the Polish Academy of Science have improved a method for calculating the migration time of drugs or drug delivery devices introduced into the sol/gel...

Displaying results 1 to 10 out of 108

1-10 Next >

© 2007-2015 BIOCOM



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%


  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%


  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%


  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%


  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues